REDWOOD CITY, Calif.,
April 30, 2019 /PRNewswire/
-- Genomic Health, Inc. (NASDAQ: GHDX) today
announced that the company will host a conference call and webcast
on Tuesday, May 7 at 4:30 p.m. Eastern Time to discuss its first
quarter 2019 financial results. The call and webcast will follow
the release of the first quarter financial results after market
close.
Conference Call Details
To access the live conference
call on May 7 at 4:30 p.m. Eastern Time via phone, please dial
(877) 303-7208 from the United
States and Canada, or +1
(224) 357-2389 internationally. The conference call ID is 6535029.
Please dial in approximately 10 minutes prior to the start of
the call.
To access the live and subsequently archived webcast of the
presentation, go to the Investor Relations section of the
company's web site at http://investor.genomichealth.com.
Please connect to the web site at least 15 minutes prior to the
presentation to allow for any software download that may be
necessary.
About Genomic Health
Genomic Health, Inc.
(NASDAQ: GHDX) is the world's leading provider of genomic-based
diagnostic tests that help optimize cancer care, including
addressing the overtreatment of the disease, one of the greatest
issues in healthcare today. With its Oncotype
IQ® Genomic Intelligence Platform, the company is
applying its world-class scientific and commercial expertise and
infrastructure to lead the translation of clinical and genomic big
data into actionable results for treatment planning throughout the
cancer patient journey, from diagnosis to treatment selection and
monitoring. The Oncotype IQ portfolio of genomic tests and services
currently consists of the company's flagship line of Oncotype
DX® gene expression tests that have been used to
guide treatment decisions for over 1 million cancer patients
worldwide. Genomic Health is expanding its test portfolio
to include additional liquid- and tissue-based tests, including the
Oncotype DX® AR-V7 Nucleus Detect™ test. The
company is based in Redwood
City, California, with international headquarters
in Geneva, Switzerland. For more information, please
visit, www.GenomicHealth.com and follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
and reported results should not be considered as an indication of
future performance. These risks and uncertainties are set forth in
our filings with the Securities and Exchange Commission, including
our most recent report on Form 10-K for the year ended December 31, 2018. These forward-looking
statements speak only as of the date hereof. Genomic Health
disclaims any obligation to update these forward-looking
statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX,
Recurrence Score, DCIS Score, Genomic Prostate Score, Oncotype DX
AR-V7 Nucleus Detect and Oncotype IQ are trademarks or registered
trademarks of Genomic Health, Inc. All other trademarks and service
marks are the property of their respective owners
GHDX-F
View original content to download
multimedia:http://www.prnewswire.com/news-releases/genomic-health-to-announce-first-quarter-2019-financial-results-and-host-conference-call-on-tuesday-may-7-2019-300836871.html
SOURCE Genomic Health, Inc.